China
· Delayed Price · Currency is CNY Sinocelltech Group Company Description
Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China.
The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E.
Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2.
The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
| Country | China |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,313 |
| CEO | Liangzhi Xie |
Contact Details
Address: No. 31 Kechuang 7th Street Beijing, 100176 China | |
| Phone | 86 10 5862 8288 |
| Website | sinocelltech.com |
Stock Details
| Ticker Symbol | 688520 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003ZL3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Liangzhi Xie | Chief Executive Officer |